hot sale Orforglipron/LY3502970/OWL833/Oral GLP-1 Receptor Agonist/Weight Management/Glycemic Control

Product Description

Orforglipron (development code LY3502970, also known as OWL833) is a synthetic non-peptide small-molecule compound with CAS number 2212020-52-3, molecular formula C₄₈H₄₈F₂N₁₀O₅ and molecular weight of 883.0. It belongs to a new generation of oral GLP-1 receptor agonists. Unlike traditional peptide-based GLP-1 agonists, it adopts a small-molecule structural design and features high oral bioavailability and administration without food restrictions, making it a highly popular research tool attracting extensive attention in the field of metabolic research. This product is a high-purity (≥98%, tested by HPLC) solid powder and can be directly used in various scientific research experiments. This product is for research use only and is not intended for human use or clinical treatment.

Key Benefits

The core characteristics of Orforglipron are "small molecule, orally available, and highly selective". It can selectively activate the glucagon-like peptide-1 receptor (GLP-1R), which plays a key role in processes such as appetite regulation, insulin secretion and energy metabolism. In vitro studies show that it has high affinity for the human GLP-1 receptor (Ki ≈ 1 nM), preferentially acts on the G protein (cAMP) signaling pathway, and is a partial agonist. Relevant studies have demonstrated that this compound exerts definite regulatory effects on blood glucose and body weight.

Specifically, its effects observed in scientific research experiments include:
Selective receptor agonism: It activates the GLP-1 receptor with high affinity and high selectivity, preferentially targeting the cAMP/G protein signaling pathway and presenting distinct signaling profiles.
Oral bioavailability: Featuring a non-peptide small-molecule structure, it can be absorbed via oral administration. This is its core advantage over injectable peptide agonists.
Body weight regulation: Significant weight reduction effects have been observed in relevant studies.
Blood glucose metabolism regulation: Research data indicate that it can improve glycemic control, offering important reference value for studies related to glucose metabolism.
Administration unrestricted by food intake: Studies show that its oral absorption is not affected by food and water intake, facilitating experimental protocol design.

Applications

Orforglipron is currently mainly used in scientific research related to metabolic diseases. It is an important tool compound for popular research directions such as type 2 diabetes and obesity, and also a representative reference molecule in the research and development of new-generation oral GLP-1 drugs. It provides a critical molecular basis for the research of metabolic drugs that "replace injections with oral administration".

Specific scientific research application scenarios include:
Study on the mechanisms of metabolic diseases: Used to explore the pathogenesis and intervention targets of diseases such as obesity and type 2 diabetes.
Receptor and signaling pathway research: Applied in in vitro experiments including the evaluation of GLP-1R agonistic activity, receptor binding assays, and studies on G protein/cAMP signaling pathways.
Reference for drug research and development: As a representative molecule of oral non-peptide GLP-1R agonists, it is used for structural optimization and lead compound screening of novel oral metabolic drugs.
In vitro cellular and molecular experiments: Suitable for cell-level receptor function assays, molecular screening and mechanism verification.
Standard reference substance: Can serve as a standard reference material in the development of related small-molecule detection methods and quality analysis.